tbuckley/cabot-search huggingface dataset:
Severe anal intraepithelial neoplasia trends and subsequent invasive anal cancer in the United States
Authors: Cameron B Haas, Eric A Engels, Joel M Palefsky, Megan A Clarke, Aimée R Kreimer, Qianlai Luo, Ruth M Pfeiffer, Baozhen Qiao, Karen S Pawlish, Analise Monterosso, Meredith S Shiels
Journal: JNCI Journal of the National Cancer Institute (2023)

Anal intraepithelial neoplasia grade III is a precursor to squamous cell carcinoma of the anus for which rates are nearly 20-fold higher in people with HIV than in the general population in the United States. We describe trends in anal intraepithelial neoplasia grade III diagnosis and risk of squamous cell carcinoma of the anus following anal intraepithelial neoplasia grade III by HIV status and sex.
Semantic cognition versus numerical cognition: a topographical perspective
Authors: Rocco Chiou, Daniel Margulies, Mojtaba Soltanlou, Elizabeth Jefferies, Roi Cohen Kadosh
Journal: Trends in Cognitive Sciences (2023)

Semantic cognition and numerical cognition are dissociable faculties with separable neural mechanisms. However, recent advances in the cortical topography of the temporal and parietal lobes have revealed a common organisational principle for the neural representations of semantics and numbers. We discuss their convergence and divergence through the prism of topography.
Novel insights into genetic susceptibility for colorectal cancer from transcriptome-wide association and functional investigation
Authors: Zhishan Chen, Wenqiang Song, Xiao-Ou Shu, Wanqing Wen, Matthew Devall, Christopher Dampier, Ferran Moratalla-Navarro, Qiuyin Cai, Jirong Long, Luc Van Kaer, Lan Wu, Jeroen R Huyghe, Minta Thomas, Li Hsu, Michael O Woods, Demetrius Albanes, Daniel D Buchanan, Andrea Gsur, Michael Hoffmeister, Pavel Vodicka, Alicja Wolk, Loic Le Marchand, Anna H Wu, Amanda I Phipps, Victor Moreno, Peters Ulrike, Wei Zheng, Graham Casey, Xingyi Guo
Journal: JNCI Journal of the National Cancer Institute (2023)

Abstract Background Transcriptome-wide association studies have been successful in identifying candidate susceptibility genes for colorectal cancer (CRC). To strengthen susceptibility gene discovery, we conducted a large transcriptome-wide association study and an alternative splicing transcriptome-wide association study in CRC using improved genetic prediction models and performed in-depth functional investigations. Methods We analyzed RNA-sequencing data from normal colon tissues and genotype data from 423 European descendants to build genetic prediction models of gene expression and alternative splicing and evaluated model performance using independent RNA-sequencing data from normal colon tissues of the Genotype-Tissue Expression Project. We applied the verified models to genome-wide association studies (GWAS) summary statistics among 58 131 CRC cases and 67 347 controls of European ancestry to evaluate associations of genetically predicted gene expression and alternative splicing with CRC risk. We performed in vitro functional assays for 3 selected genes in multiple CRC cell lines. Results We identified 57 putative CRC susceptibility genes, which included the 48 genes from transcriptome-wide association studies and 15 genes from splicing transcriptome-wide association studies, at a Bonferroni-corrected P value less than .05. Of these, 16 genes were not previously implicated in CRC susceptibility, including a gene PDE7B (6q23.3) at locus previously not reported by CRC GWAS. Gene knockdown experiments confirmed the oncogenic roles for 2 unreported genes, TRPS1 and METRNL, and a recently reported gene, C14orf166. Conclusion This study discovered new putative susceptibility genes of CRC and provided novel insights into the biological mechanisms underlying CRC development.
Thermal Pulsation in the Management of Meibomian Gland Dysfunction and Dry Eye
Authors: Jeremiah P. Tao, Joanne F. Shen, Vinay K. Aakalu, Jill A. Foster, Suzanne K. Freitag, Timothy J. McCulley, M. Reza Vagefi, Stephen J. Kim, Edward J. Wladis
Journal: Ophthalmology (2023)
A bio-inspired nanoparticle coating for vascular healing and immunomodulatory by cGMP-PKG and NF-kappa B signaling pathways
Authors: Yanyan Li, Bo Zhang, Xiyu Liu, Huining Wan, Yumei Qin, Hui Yan, Yu Wang, Yongqi An, Yuan Yang, Yan Dai, Li Yang, Yunbing Wang
Journal: Biomaterials (2023)
Cross-species oncogenomics offers insight into human muscle-invasive bladder cancer
Authors: Kim Wong, Federico Abascal, Latasha Ludwig, Heike Aupperle-Lellbach, Julia Grassinger, Colin W. Wright, Simon J. Allison, Emma Pinder, Roger M. Phillips, Laura P. Romero, Arnon Gal, Patrick J. Roady, Isabel Pires, Franco Guscetti, John S. Munday, Maria C. Peleteiro, Carlos A. Pinto, Tânia Carvalho, João Cota, Elizabeth C. Du Plessis, Fernando Constantino-Casas, Stephanie Plog, Lars Moe, Simone de Brot, Ingrid Bemelmans, Renée Laufer Amorim, Smitha R. Georgy, Justina Prada, Jorge del Pozo, Marianne Heimann, Louisiane de Carvalho Nunes, Outi Simola, Paolo Pazzi, Johan Steyl, Rodrigo Ubukata, Peter Vajdovich, Simon L. Priestnall, Alejandro Suárez-Bonnet, Franco Roperto, Francesca Millanta, Chiara Palmieri, Ana L. Ortiz, Claudio S. L. Barros, Aldo Gava, Minna E. Söderström, Marie O’Donnell, Robert Klopfleisch, Andrea Manrique-Rincón, Inigo Martincorena, Ingrid Ferreira, Mark J. Arends, Geoffrey A. Wood, David J. Adams, Louise van der Weyden
Journal: Genome biology (2023)

Abstract Background In humans, muscle-invasive bladder cancer (MIBC) is highly aggressive and associated with a poor prognosis. With a high mutation load and large number of altered genes, strategies to delineate key driver events are necessary. Dogs and cats develop urothelial carcinoma (UC) with histological and clinical similarities to human MIBC. Cattle that graze on bracken fern also develop UC, associated with exposure to the carcinogen ptaquiloside. These species may represent relevant animal models of spontaneous and carcinogen-induced UC that can provide insight into human MIBC. Results Whole-exome sequencing of domestic canine ( n = 87) and feline ( n = 23) UC, and comparative analysis with human MIBC reveals a lower mutation rate in animal cases and the absence of APOBEC mutational signatures. A convergence of driver genes ( ARID1A, KDM6A, TP53 , FAT1 , and NRAS ) is discovered, along with common focally amplified and deleted genes involved in regulation of the cell cycle and chromatin remodelling. We identify mismatch repair deficiency in a subset of canine and feline UCs with biallelic inactivation of MSH2 . Bovine UC ( n = 8) is distinctly different; we identify novel mutational signatures which are recapitulated in vitro in human urinary bladder UC cells treated with bracken fern extracts or purified ptaquiloside. Conclusion Canine and feline urinary bladder UC represent relevant models of MIBC in humans, and cross-species analysis can identify evolutionarily conserved driver genes. We characterize mutational signatures in bovine UC associated with bracken fern and ptaquiloside exposure, a human-linked cancer exposure. Our work demonstrates the relevance of cross-species comparative analysis in understanding both human and animal UC.
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
Authors: Gi-Ae Kim, Joon Ho Moon, Won Kim
Journal: Clinical and Molecular Hepatology (2023)

The existing term non-alcoholic fatty liver disease (NAFLD) has raised substantial concerns due to its inherent disadvantages of using exclusionary diagnostic criteria and the stigmatizing word 'fatty.' Three pan-national liver associations set out to explore a new nomenclature to replace both NAFLD and its suggested alternative, metabolic (dysfunction)-associated fatty liver disease (MAFLD). They surveyed if a change in nomenclature and/or definition is favored and which nomenclature best communicates disease characteristics and increases awareness. In lieu of NAFLD/MAFLD, metabolic dysfunction-associated steatotic liver disease (MASLD) has been chosen, and an umbrella term, steatotic liver disease (SLD), encompassing the whole spectrum of liver disease, has been proposed. It has been suggested that cardiometabolic risk factors should be considered when categorizing SLD patients. Furthermore, a new subcategory, MASLD with increased alcohol intake (MetALD), casts light on a neglected group of patients with moderate or more alcohol consumption. The importance of metabolic dysfunction was acknowledged in this new nomenclature, but the precise contribution of metabolic dysfunction and alcohol consumption to the development and progression of SLD remains unclear. Herein, we review hepatologists' and endocrinologists' perspectives on the new nomenclature, along with its possible impact on clinical practice. Although it is premature to predict the settlement of the new nomenclature, this review may help build more evidence for a soft landing of it in the future.
Early GCase activity is a predictor of long-term cognitive decline in Parkinson’s disease
Authors: Linn Oftedal, Johannes Lange, Kenn Freddy Pedersen, Aleksander Hagen Erga, Ingvild Dalen, Ole-Bjørn Tysnes, Guido Alves, Jodi Maple-Grødem
Journal: Translational Neurodegeneration (2023)
Differences between heart failure specialists and non‐specialists regarding heart failure drug implementation and up‐titration
Authors: Charles Fauvel, Clara Ines Saldarriaga Giraldo, Anders Barassa, Anastasia Shchendrygina, Massimo Mapelli, Nina Jakus, Antoine Jobbe‐Duval, Anja Zupan Meznar, Brahim Harbaoui, Emmanuelle Berthelot, François Roubille, Giuseppe Rosano, Nathan Mewton
Journal: European Journal of Heart Failure (2023)

à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Aortic regurgitation for adverse cardiovascular events: Really harmless or just hidden? Letter regarding the article ‘Prevalence, characteristics and prognostic impact of aortic valve disease in patients with heart failure and reduced, mildly reduced, and preserved ejection fraction: An analysis of the <scp>ESC</scp> Heart Failure Long‐Term Registry’
Authors: Qingqing Zhu, Sibo Wang
Journal: European Journal of Heart Failure (2023)
Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post‐discharge period: The multinational randomized <scp>LeoDOR</scp> trial
Authors: Gerhard Pölzl, Johann Altenberger, Josep Comín‐Colet, Juan F. Delgado, Francesco Fedele, Martín Jesús García‐González, Finn Gustafsson, Josep Masip, Zoltán Papp, Stefan Störk, Hanno Ulmer, Sarah Maier, Bojan Vrtovec, Gerhard Wikström, Endre Zima, Axel Bauer
Journal: European Journal of Heart Failure (2023)

The LeoDOR trial explored the efficacy and safety of intermittent levosimendan therapy in the vulnerable phase following a hospitalization for acute heart failure (HF).In this prospective multicentre, double-blind, two-armed trial, patients with advanced HF were randomized 2:1 at the end of an index hospitalization for acute HF to intermittent levosimendan therapy or matching placebo for 12 weeks. All patients had left ventricular ejection fraction (LVEF) ≤30% during index hospitalization. Levosimendan was administered according to centre preference either as 6 h infusion at a rate of 0.2 μg/kg/min every 2 weeks, or as 24 h infusion at a rate of 0.1 μg/kg/min every 3 weeks. The primary efficacy assessment after 14 weeks was based on a global rank score consisting of three hierarchical groups. Secondary clinical endpoints included the composite risk of tiers 1 and 2 at 14 and 26 weeks, respectively. Due to the COVID-19 pandemic, the planned number of patients could not be recruited. The final modified intention-to-treat analysis included 145 patients (93 in the combined levosimendan arm, 52 in the placebo arm), which reduced the statistical power to detect a 20% risk reduction in the primary endpoint to 60%. Compared with placebo, intermittent levosimendan had no significant effect on the primary endpoint: the mean rank score was 72.55 for the levosimendan group versus 73.81 for the placebo group (p = 0.863). However, there was a signal towards a higher incidence of the individual clinical components of the primary endpoint in the levosimendan group versus the placebo group both after 14 weeks (hazard ratio [HR] 2.94, 95% confidence interval [CI] 1.12-7.68; p = 0.021) and 26 weeks (HR 1.64, 95% CI 0.87-3.11; p = 0.122).Among patients recently hospitalized with HF and reduced LVEF, intermittent levosimendan therapy did not improve post-hospitalization clinical stability.
Intravitreal implants manufactured by supercritical foaming for treating retinal diseases
Authors: Carlos Bendicho-Lavilla, Iria Seoane-Viaño, Víctor Santos-Rosales, Victoria Díaz-Tomé, María Carracedo-Pérez, Asteria M. Luzardo-Álvarez, Carlos A. García-González, Francisco J. Otero-Espinar
Journal: Journal of Controlled Release (2023)

Chronic retinal diseases, such as age-related macular degeneration (AMD), are a major cause of global visual impairment. However, current treatment methods involving repetitive intravitreal injections pose financial and health burdens for patients. The development of controlled drug release systems, particularly for biological drugs, is still an unmet need in prolonging drug release within the vitreous chamber. To address this, green supercritical carbon dioxide (scCO2) foaming technology was employed to manufacture porous poly(lactic-co-glycolic acid) (PLGA)-based intravitreal implants loaded with dexamethasone. The desired implant dimensions were achieved through 3D printing of customised moulds. By varying the depressurisation rates during the foaming process, implants with different porosities and dexamethasone release rates were successfully obtained. These implants demonstrated controlled drug release for up to four months, surpassing the performance of previously developed implants. In view of the positive results obtained, a pilot study was conducted using the monoclonal antibody bevacizumab to explore the feasibility of this technology for preparing intraocular implants loaded with biologic drug molecules. Overall, this study presents a greener and more sustainable alternative to conventional implant manufacturing techniques, particularly suited for drugs that are susceptible to degradation under harsh conditions.
Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from <scp>DELIVER</scp>
Authors: Jawad H. Butt, Henri Lu, Toru Kondo, Erasmus Bachus, Rudolf A. de Boer, Silvio E. Inzucchi, Pardeep S. Jhund, Mikhail N. Kosiborod, Carolyn S.P. Lam, Felipe A. Martinez, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray
Journal: European Journal of Heart Failure (2023)

Chronic obstructive pulmonary disease (COPD) is common in heart failure with a mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and is associated with worse outcomes. In a pre-specified analysis of DELIVER, we investigated the relationship between COPD status and outcomes, and the efficacy and safety of dapagliflozin, compared with placebo, according to COPD status.Patients with severe pulmonary disease (including COPD) were excluded from the trial. The primary outcome was a composite of cardiovascular death or worsening heart failure. Of the 6261 patients with data on baseline COPD status, 694 (11.1%) had a known history of this condition. The risk of the primary endpoint was higher in patients with mild-to-moderate COPD compared with those without COPD (adjusted hazard ratio [HR] 1.28, 95% confidence interval [CI] 1.08-1.51). The benefit of dapagliflozin on the primary outcome was consistent irrespective of COPD status (no COPD: HR 0.82 [95% CI 0.72-0.93]; COPD: HR 0.82 [95% CI 0.62-1.10]; pinteraction = 0.98). Consistent effects were observed for heart failure, cardiovascular, and all-cause hospitalization, and deaths, and composites of these. Dapagliflozin, as compared with placebo, improved the Kansas City Cardiomyopathy Questionnaire scores from baseline to 8 months to a similar extent in patients with and without mild-to-moderate COPD (pinteraction ≥ 0.63). Adverse events and treatment discontinuation were not more frequent with dapagliflozin than with placebo irrespective of COPD status.Mild-to-moderate COPD is common in patients with HFmrEF/HFpEF and is associated with worse outcomes. The beneficial effects of dapagliflozin compared with placebo on clinical events and symptoms were consistent, regardless of COPD status.ClinicalTrials.gov NCT03619213.
Optical Coherence Tomography–Guided or Intravascular Ultrasound–Guided Percutaneous Coronary Intervention: The OCTIVUS Randomized Clinical Trial
Authors: Do-Yoon Kang, Jung-Min Ahn, Sung-Cheol Yun, Seung-Ho Hur, Yun-Kyeong Cho, Cheol Hyun Lee, Soon Jun Hong, Subin Lim, Sang-Wook Kim, Hoyoun Won, Jun-Hyok Oh, Jeong Cheon Choe, Young Joon Hong, Yong-Hoon Yoon, Hoyun Kim, Yeonwoo Choi, Jinho Lee, Young Won Yoon, Soo-Joong Kim, Jang-Ho Bae, Duk-Woo Park, Seung-Jung Park
Journal: Circulation (2023)

Intravascular imaging-guided percutaneous coronary intervention (PCI) with intravascular ultrasound (IVUS) or optical coherence tomography (OCT) showed superior clinical outcomes compared with angiography-guided PCI. However, the comparative effectiveness of OCT-guided and IVUS-guided PCI regarding clinical outcomes is unknown.In this prospective, multicenter, open-label, pragmatic trial, we randomly assigned 2008 patients with significant coronary artery lesions undergoing PCI in a 1:1 ratio to undergo either an OCT-guided or IVUS-guided PCI. The primary end point was a composite of death from cardiac causes, target vessel-related myocardial infarction, or ischemia-driven target-vessel revascularization at 1 year, which was powered for noninferiority of the OCT group compared with the IVUS group. Safety outcomes were also assessed.At 1 year, primary end point events occurred in 25 of 1005 patients (Kaplan-Meier estimate, 2.5%) in the OCT group and in 31 of 1003 patients (Kaplan-Meier estimate, 3.1%) in the IVUS group (absolute difference, -0.6 percentage points; upper boundary of one-sided 97.5% CI, 0.97 percentage points; P<0.001 for noninferiority). The incidence of contrast-induced nephropathy was similar (14 patients [1.4%] in the OCT group versus 15 patients [1.5%] in the IVUS group; P=0.85). The incidence of major procedural complications was lower in the OCT group than in the IVUS group (22 [2.2%] versus 37 [3.7%]; P=0.047), although imaging procedure-related complications were not observed.In patients with significant coronary artery lesions, OCT-guided PCI was noninferior to IVUS-guided PCI with respect to the incidence of a composite of death from cardiac causes, target vessel-related myocardial infarction, or ischemia-driven target-vessel revascularization at 1 year. The selected study population and lower-than-expected event rates should be considered in interpreting the trial.URL: https://www.gov; Unique number: NCT03394079.
Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
Authors: Arleigh McCurdy, Hira Mian, Richard LeBlanc, Victor H. Jimenez-Zepeda, Jiandong Su, Esther Masih-Khan, Alissa Visram, Martha Louzada, Kevin Song, Darrell White, Michael Sebag, Julie Stakiw, Anthony Reiman, Muhammad Aslam, Debra Bergstrom, Rami Kotb, Rayan Kaedbey, Engin Gul, Donna Reece, Christopher P. Venner
Journal: Blood Cancer Journal (2023)

Table 2. Multivariable model showing factors associated with attrition at each line of therapy by ASCT status.
Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation
Authors: Vivek Y. Reddy, Edward P. Gerstenfeld, Andrea Natale, William Whang, Frank A. Cuoco, Chinmay Patel, Stavros E. Mountantonakis, Douglas N. Gibson, John D. Harding, Christopher R. Ellis, Kenneth A. Ellenbogen, David B. DeLurgio, Jose Osorio, Anitha B. Achyutha, Christopher W. Schneider, Andrew S. Mugglin, Elizabeth M. Albrecht, Kenneth M. Stein, John W. Lehmann, Moussa Mansour
Journal: New England Journal of Medicine (2023)

Catheter-based pulmonary vein isolation is an effective treatment for paroxysmal atrial fibrillation. Pulsed field ablation, which delivers microsecond high-voltage electrical fields, may limit damage to tissues outside the myocardium. The efficacy and safety of pulsed field ablation as compared with conventional thermal ablation are not known.
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
Authors: Barry A. Borlaug, Dalane W. Kitzman, Melanie J. Davies, Søren Rasmussen, Eric Barros, Javed Butler, Mette Nygaard Einfeldt, G. Kees Hovingh, Daniél Vega Møller, Mark C. Petrie, Sanjiv J. Shah, Subodh Verma, Walter Abhayaratna, Fozia Z. Ahmed, Vijay Chopra, Justin Ezekowitz, Michael Fu, Hiroshi Ito, Małgorzata Lelonek, Vojtech Melenovsky, Julio Núñez, Eduardo Perna, Morten Schou, Michele Senni, Peter van der Meer, Dirk Von Lewinski, Dennis Wolf, Mikhail N. Kosiborod
Journal: Nature Medicine (2023)

In the STEP-HFpEF trial, semaglutide improved symptoms, physical limitations and exercise function and reduced body weight in patients with obesity phenotype of heart failure and preserved ejection fraction (HFpEF). This prespecified analysis examined the effects of semaglutide on dual primary endpoints (change in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) and body weight) and confirmatory secondary endpoints (change in 6-minute walk distance (6MWD), hierarchical composite (death, HF events, change in KCCQ-CSS and 6MWD) and change in C-reactive protein (CRP)) across obesity classes I-III (body mass index (BMI) 30.0-34.9 kg m